Among the 149 genes involved in molecular pathways possibly determining the clinicopathological diversity of NASH-related HCCs listed in Table 2, taking into consideration their literature-based implications in the process of carcinogenesis, we further focused on the SPHK1, INHBA, LTB and PDE3B genes. The gene discussed is SPHK1; the disease is metabolic dysfunction-associated steatohepatitis.